Clinical Pharmacology (Formerly PK) Expert Working Group

History

The IPSG Clinical Pharmacology Expert Working Group was founded in 2009. Initially known as the IPSG Pharmacokinetics Expert Working Group, the group aims to investigate the pharmacokinetic and pharmacodynamic relationship between factor and non-factor exposure and bleeding, clinical or subclinical outcomes. The group’s members are dedicated to evaluating various methodologies and approaches for exploring the links between specific pharmacokinetic parameters of relevant medications or therapies and genotype phenotype correlations.

The IPSG Pharmacokinetics Expert Working Group held their 1st meeting in March 2009. At the meeting, the group developed a review article on the implications of pharmacokinetics of coagulation factor VIII and IX. In 2010, the manuscript titled “Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment.” was published in Haemophilia. More recently, an educational manuscript was developed addressing the various issues surrounding the use of pharmacokinetic assessment tools with a focus on haemophilia B and extended half-life products. The group is currently looking towards gene therapy and non-factor concentrate treatments and their optimal use in hemophilia A and B and is open to consider clinical pharmacology of treatments for other rare bleeding disorders.

Citation: Collins, PW et al. on behalf of the Pharmacokinetics in Prophylaxis Expert Working Group of the International Prophylaxis Study Group Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment. Haemophilia 2011 Jan; 17(1):2-10.